Literature DB >> 16857839

Method of defining equol-producer status and its frequency among vegetarians.

Kenneth D R Setchell1, Sidney J Cole.   

Abstract

7-Hydroxy-3-(4'-hydroxyphenyl)-chroman (S-equol) is a specific end-metabolite formed in the biotransformation of the dietary soy isoflavones daidzin and daidzein by intestinal bacteria. The frequency of equol production varies among individuals and populations, and it is suggested that the efficacy of soy foods differs depending on the ability of an individual to produce equol. To develop a standardized approach to define equol-producer status that can be universally adopted to differentiate these 2 distinct populations, we measured isoflavones in serum and urine collected from a cohort of 41 healthy adults, comprising 29 vegetarians and 12 nonvegetarians, after consuming 2 x 250 mL/d soy milk on 3 consecutive days. Serum and urinary daidzein and S-equol concentrations were analyzed by MS. Serum S-equol and daidzein concentrations ranged from 10.3-139 nmol/L (2.5-33.6 microg/L) and 16-1401 nmol/L (4.0-356 microg/L), respectively, whereas in urine the corresponding concentrations ranged from 16-12,574 nmol/L (4-3043 microg/L) and 539-26,834 nmol/L (137-6816 microg/L), respectively. The log10-transformed urinary S-equol:daidzein ratio provided a clearer distinction of equol-producer status than the absolute serum or urinary S-equol concentrations because it is independent of isoflavone intake and minimizes interindividual variation in isoflavone pharmacokinetics or differences in analytical methodologies. A threshold value for the log10-transformed urinary S-equol:daidzein ratio of -1.75 provided a demarcation to define equol-producer status. The frequency of equol producers in the vegetarians was 59%, similar to the reported frequency in Japanese adults consuming soy, and much higher than for nonvegetarian adults (25%), suggesting that dietary components other than soy influence S-equol synthesis by intestinal bacteria.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16857839     DOI: 10.1093/jn/136.8.2188

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  110 in total

Review 1.  Equol: history, chemistry, and formation.

Authors:  Kenneth D R Setchell; Carlo Clerici
Journal:  J Nutr       Date:  2010-06-02       Impact factor: 4.798

2.  Soy isoflavone phase II metabolism differs between rodents and humans: implications for the effect on breast cancer risk.

Authors:  Kenneth D R Setchell; Nadine M Brown; Xueheng Zhao; Stephanie L Lindley; James E Heubi; Eileen C King; Mark J Messina
Journal:  Am J Clin Nutr       Date:  2011-09-28       Impact factor: 7.045

3.  Soy isoflavone supplementation for breast cancer risk reduction: a randomized phase II trial.

Authors:  Seema A Khan; Robert T Chatterton; Nancy Michel; Michelle Bryk; Oukseub Lee; David Ivancic; Richard Heinz; Carola M Zalles; Irene B Helenowski; Borko D Jovanovic; Adrian A Franke; Maarten C Bosland; Jun Wang; Nora M Hansen; Kevin P Bethke; Alexander Dew; Margerie Coomes; Raymond C Bergan
Journal:  Cancer Prev Res (Phila)       Date:  2012-02

4.  The effects of soy consumption before diagnosis on breast cancer survival: the Multiethnic Cohort Study.

Authors:  Shannon M Conroy; Gertraud Maskarinec; Song-Yi Park; Lynne R Wilkens; Brian E Henderson; Laurence N Kolonel
Journal:  Nutr Cancer       Date:  2013       Impact factor: 2.900

Review 5.  Flavonoids and age-related disease: risk, benefits and critical windows.

Authors:  J K Prasain; S H Carlson; J M Wyss
Journal:  Maturitas       Date:  2010-02-23       Impact factor: 4.342

6.  Potentiation of brain mitochondrial function by S-equol and R/S-equol estrogen receptor β-selective phytoSERM treatments.

Authors:  Jia Yao; Liqin Zhao; Zisu Mao; Shuhua Chen; Karren Carmen Wong; Jimmy To; Roberta Diaz Brinton
Journal:  Brain Res       Date:  2013-02-18       Impact factor: 3.252

7.  S-(-)equol producing status not associated with breast cancer risk among low isoflavone-consuming US postmenopausal women undergoing a physician-recommended breast biopsy.

Authors:  Mandeep K Virk-Baker; Stephen Barnes; Helen Krontiras; Tim R Nagy
Journal:  Nutr Res       Date:  2013-12-18       Impact factor: 3.315

8.  Urinary phytoestrogen excretion and postmenopausal breast cancer risk: the multiethnic cohort study.

Authors:  Marc T Goodman; Yurii B Shvetsov; Lynne R Wilkens; Adrian A Franke; Loic Le Marchand; Kerry K Kakazu; Abraham M Y Nomura; Brian E Henderson; Laurence N Kolonel
Journal:  Cancer Prev Res (Phila)       Date:  2009-09-29

9.  A preliminary study of the safety, feasibility and cognitive efficacy of soy isoflavone supplements in older men and women.

Authors:  Carey E Gleason; Cynthia M Carlsson; Jodi H Barnet; Sarah A Meade; Kenneth D R Setchell; Craig S Atwood; Sterling C Johnson; Michele L Ries; Sanjay Asthana
Journal:  Age Ageing       Date:  2008-12-02       Impact factor: 10.668

10.  Urinary phytoestrogen excretion and prostate cancer risk: a nested case-control study in the Multiethnic Cohort.

Authors:  S-Y Park; L R Wilkens; A A Franke; L Le Marchand; K K Kakazu; M T Goodman; S P Murphy; B E Henderson; L N Kolonel
Journal:  Br J Cancer       Date:  2009-06-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.